A Second Team Pursues Cimavax Commercialization in the U.S.

A Second Team Pursues Cimavax Commercialization in the U.S.

Cuba’s Cimavax gained media attention last month when Roswell Park Cancer Institute in Buffalo, New York announced that the U.S. Food and Drug Administration (FDA) had approved clinical trials there as part of a collaboration with Cuba’s Center for Molecular Immunology. But there are actually two parallel medical initiatives pursuing commercialization of the human cancer … Read more